Pfizer Inc. Press Releases https://investors.pfizer.com/generated by Q4Fri, 03 Apr 2026 18:24:09 -0400Copyright Q4 Inc. All rights reserved.Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts3c81e691-874d-40e2-9cb9-0916d51ceaffhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Public-to-View-and-Listen-to-Webcast-of-May-5-Conference-Call-with-Analysts/default.aspxTue, 24 Mar 2026 10:00:00 -0400Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Triald706e687-95b3-4ca8-9233-a35cb6fff2dfhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-and-Valneva-Announce-Lyme-Disease-Vaccine-Candidate-Demonstrates-Strong-Efficacy-in-Phase-3-VALOR-Trial/default.aspxMon, 23 Mar 2026 06:45:00 -0400Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC081be1ac-b071-4f66-8517-a56200fa3744https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Recommends-Shareholders-Reject-the-Mini-Tender-Offer-by-Tutanota-LLC/default.aspxFri, 20 Mar 2026 16:30:00 -0400TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancerbc26d103-3a70-4ac6-911a-1244f51fb821https://investors.pfizer.com/Investors/news-events/News/news-details/2026/TALZENNA-Plus-XTANDI-Significantly-Improves-Radiographic-Progression-Free-Survival-in-Metastatic-Prostate-Cancer/default.aspxThu, 19 Mar 2026 06:45:00 -0400Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer4c3284b7-cc15-426f-97ee-ae9ea770cba5https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Announces-Positive-Topline-Phase-2-Results-for-Next-Generation-CDK4-Inhibitor-Atirmociclib-in-Second-Line-Metastatic-Breast-Cancer/default.aspxTue, 17 Mar 2026 06:45:00 -0400Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis7c2bc3b7-8434-423e-a3e1-93b94a35eb35https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizers-Phase-2-Study-of-Trispecific-Antibody-Positive-in-Moderate-to-Severe-Atopic-Dermatitis/default.aspxMon, 09 Mar 2026 06:45:00 -0400PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancerdb515e85-2e93-48eb-b5f6-3e29d43a16d6https://investors.pfizer.com/Investors/news-events/News/news-details/2026/PADCEV--Keytruda-Cuts-Risk-of-Recurrence-or-Death-by-Nearly-50-in-Cisplatin-Eligible-Muscle-Invasive-Bladder-Cancer/default.aspxFri, 27 Feb 2026 10:00:00 -0500U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer9e7a33ec-fb93-4569-b967-5d37bff58c73https://investors.pfizer.com/Investors/news-events/News/news-details/2026/U-S--FDA-Grants-Full-Approval-to-Pfizers-BRAFTOVI-Combination-Regimen-in-First-Line-Metastatic-Colorectal-Cancer/default.aspxTue, 24 Feb 2026 14:29:00 -0500Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference5ad89857-ac1f-490d-92f9-ca0cef005bbbhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Public-to-Listen-to-Webcast-of-Pfizer-Discussion-at-Healthcare-Conference/default.aspxMon, 23 Feb 2026 10:00:00 -0500Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer246b4708-3be0-4218-a801-85ebdf38f3b0https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizers-BRAFTOVI-Regimen-Improves-Progression-Free-Survival-in-Metastatic-Colorectal-Cancer/default.aspxTue, 17 Feb 2026 06:45:00 -0500